Focus: Engine Biosciences is a 2023-founded AI & genomics-focused biotech headquartered in Redwood City, CA, operating a hybrid business model combining generic commercialization with early-stage pipeline development across five therapeutic areas.
Profile data last refreshed 22h ago · AI intelligence enriched 1mo ago
Early-stage opportunity for technologists willing to stomach generic pharma fundamentals, but venture-scale runway and pipeline depth do not yet justify biotech-level career risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Dominant revenue pillar (69% of total) but off-patent generic with structural decline risk; represents legacy revenue base, not growth engine.
Help build intelligence for Engine Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Engine Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Secondary revenue contributor (~30% of revenue) for immunosuppressive applications; post-LOE generic with limited upside.
Niche psychiatric/menopausal indication with minimal revenue contribution; post-LOE generic with little strategic value.
Minimal revenue contributor; post-LOE antibiotic generic with negligible commercial significance.
Only NDA-backed branded product with 2030 LOE; represents sole proprietary asset but negligible current revenue ($5K).
Post-LOE COX-2 inhibitor with no disclosed Part D spending; commercial contribution unclear.
Aromatase inhibitor for advanced breast cancer; post-LOE generic with no disclosed Part D spending.
Duplicate entry reflecting duplicate aromatase inhibitor listing in source data.
Duplicate entry reflecting duplicate aromatase inhibitor listing in source data.
26 discontinued, 35 duplicate formulations not shown
+13 more products
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo